Emory University; Winship Cancer Institute

Atlanta, Georgia 404-778-5747

26 studies enrolling now · 283 studies all time

What they study most

Accelerated Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia, Acute Myelogenous Leukemia (AML), Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Adult, Acute Myelogenous Leukemia, Relapsed, Adult

Studies at this site

• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — Recruiting now
• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) — Recruiting now
• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer — Recruiting now
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In — Recruiting now
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study — Recruiting now
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer — Recruiting now
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — Recruiting now
• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab — Recruiting now
• Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial — Recruiting now
• The PREDICT Registry: — Recruiting now
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma — Recruiting now
• Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer — Recruiting now
• Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer — Recruiting now
• A Web-Based Dyadic Intervention for Colorectal Cancer — Recruiting now
• A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) — Recruiting now
• Tumor Treating Fields for the Treatment of Brainstem Gliomas — Recruiting now
• Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers — Recruiting now
• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma — Recruiting now
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer — Recruiting now
• ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer — Recruiting now
• A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) — Recruiting now
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy — Running, not enrolling
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — Running, not enrolling
• Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer — Running, not enrolling
• Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy — Running, not enrolling
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU — Stopped early
• Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency — Running, not enrolling
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer — Completed
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Running, not enrolling
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery — Completed
• Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer — Stopped early
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders — Running, not enrolling
• A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study — Completed
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant — Completed
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Running, not enrolling
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer — Running, not enrolling
• Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas — Running, not enrolling
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses — Completed
• Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers — Completed
• Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab — Completed
• Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases — Completed
• Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer — Completed
• Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer — Completed
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) — Completed